[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599310":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":76,"collaborators":11,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Centessa Pharmaceuticals (UK) Limited","INDUSTRY",[8,15,18,21,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: SAD Study in Healthy Adults","EXPERIMENTAL",null,[13,14],"Drug: ORX142 Tablets","Other: Placebo Tablets",{"label":16,"type":10,"description":11,"interventionNames":17},"Part B: Food-effect Evaluation in Healthy Adults",[13],{"label":19,"type":10,"description":11,"interventionNames":20},"Part C: MAD Study in Healthy Adults",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Part D: Evaluation of a Single Dose in Healthy Older Adults",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"Part E: PoC Study in Acutely Sleep-deprived Healthy Adults",[13,14],[28,32],{"type":29,"name":30,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","ORX142 Tablets",[9,16,19,22,25],{"type":33,"name":34,"description":34,"armGroupLabels":35,"otherNames":11},"OTHER","Placebo Tablets",[9,19,22,25],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"ORX142 Centessa Program Lead","CONTACT","617-468-5770","ORX142-0101study@centessa.com",[43,57,67],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":11},"Site #1","RECRUITING","Lincoln","Nebraska","68502","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-96.66696,40.8,{"lat":55,"lon":54},{"facility":58,"status":45,"city":59,"state":60,"zip":61,"country":49,"countryCode":50,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"Site #2","Eatontown","New Jersey","07724",{"type":52,"coordinates":63},[64,65],-74.05097,40.29622,{"lat":65,"lon":64},{"facility":68,"status":45,"city":69,"state":69,"zip":70,"country":49,"countryCode":50,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Site #3","New York","10019",{"type":52,"coordinates":72},[73,74],-74.00597,40.71427,{"lat":74,"lon":73},{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100599310","phase-1-a-study-of-orx142-in-healthy-adult-subjects-including-subjects-18-to-80-years-of-age-100599310",false,"NCT07082829","A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age","A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects","Key Inclusion Criteria:\n\n1. Healthy males or females as determined by assessments at the Screening Visit.\n\n   For Parts A, B, C, and E:\n\n   a. Participants must be at least 18 years of age and no more than 55 years of age at the Screening\n2. For Part D:\n\na .Participants must be at least 60 years of age and no more than 80 years of age at the Screening\n\nKey Exclusion Criteria:\n\n1. Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.\n2. History of seizure disorder, any other condition that increases the risk of seizure\n3. Has a clinically significant sleep disorder, including insomnia or sleep apnea.",true,"ALL","18 Years","80 Years",{"count":90,"type":91},208,"ESTIMATED","INTERVENTIONAL",[94],"PHASE1","Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.",[97],"Excessive Daytime Sleepiness",[97,99],"orexin-2 receptor agonist","2025-12-17",{"date":102,"type":103},"2025-12-24","ACTUAL",{"date":105,"type":103},"2025-06-30",{"date":107,"type":91},"2026-06-15",{"name":5,"class":6},3]